LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Randox Presents Future of Diagnostic Technology

By LabMedica International staff writers
Posted on 21 May 2023
Print article
Image: The Vivalytic all-in-one solution for molecular diagnostics (Photo courtesy of Randox)
Image: The Vivalytic all-in-one solution for molecular diagnostics (Photo courtesy of Randox)

Randox Laboratories (Crumlin, UK) is showcasing its extensive range of innovative products that are revolutionizing healthcare at the 2023 EuroMedLab Congress.

At EuroMedLab Rome 2023, Randox is introducing the new Acusera third-party controls designed for comprehensive test menu consolidation in laboratory internal quality control. These third-party controls are "true," meaning they are not biased towards or optimized for any specific reagent, method, or instrument, and hence offer an objective assessment of performance. Notably, several Acusera controls are produced using 100% human materials, mimicking a patient sample's behavior and thus providing an accurate reflection of the test system's performance.

Also on display at the industry event is Randox's Vivalytic, an all in one molecular diagnostic solution. This compact benchtop platform consolidates the complete molecular workflow, including extraction, PCR amplification, and detection. The unique multiplex Biochip Technology from Randox powers the Vivalytic, yielding multiple results from a single patient sample. The biochip detection system based on a chemiluminescent signal, which is the emission of light without heat from a chemical reaction. Each biochip is pre-engineered with spatially distinct testing regions (DTRs), each representing an individual test. Each DTR can be occupied with oligonucleotides specific to a pathogen or target of interest, allowing the high-plex capabilities of the Biochip Technology to eliminate the need for running multiple, time-consuming, and sample-intensive assays.

Randox is holding live demonstrations of ACUSERA 24•7 Interlaboratory Data Management which provides instant access to an unrivalled range of features including QC multi-rules, interactive charts, live peer group data, automatic calculation of Measurement Uncertainty & Sigma Metrics & a unique dashboard interface, all designed to speed up the review process and provide at-a-glance performance assessment. Randox is also demonstrating RIQAS (Randox International Quality Assessment Scheme which is used by more than 55,000 laboratory participants in 134 countries and accredited to ISO 17043. As a result, Randox has RIQAS users on every continent who are registered for one or more of its 36 flexible EQA programs, utilizing the available data to ensure the quality and reliability of their results.

ACUSERA 24•7 Interlaboratory Data Management, a feature-rich platform offering QC multi-rules, interactive charts, live peer group data, automatic calculation of Measurement Uncertainty & Sigma Metrics & a unique dashboard interface. All these features are designed to expedite the review process and provide at-a-glance performance assessment. Further, Randox is also demonstrating its RIQAS (Randox International Quality Assessment Scheme), an ISO 17043-accredited scheme employed by over 55,000 lab participants across 134 countries. Thanks to its global footprint, Randox has RIQAS users in every continent who are registered for one or more of its 36 flexible EQA programs, thereby leveraging available data to assure the quality and dependability of their results.

Related Links:
Randox Laboratories 

Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Multi-Function Pipetting Platform
apricot PP5
New
Centromere B Assay
Centromere B Test

Print article

Channels

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Sekisui Diagnostics UK Ltd.